British Journal of Cancer最新文献_第3页

Novel mutations of SRPX facilitate the stemness and malignant progression of glioma. SRPX的新突变促进胶质瘤的发生和恶性进展。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2025-07-15 DOI: 10.1038/s41416-025-03091-5

Siyuan Tang, Chunhui Qu, Mingyu Zhang, Peijun Zhou, Xingzhi Peng, Zhuan Zhou, Liangfang Shen, Lifang Yang

{"title":"Novel mutations of SRPX facilitate the stemness and malignant progression of glioma.","authors":"Siyuan Tang, Chunhui Qu, Mingyu Zhang, Peijun Zhou, Xingzhi Peng, Zhuan Zhou, Liangfang Shen, Lifang Yang","doi":"10.1038/s41416-025-03091-5","DOIUrl":"https://doi.org/10.1038/s41416-025-03091-5","url":null,"abstract":"Background: Explorations of genomic profiles are of great clinical significance for glioma due to the high tumor heterogeneity and stemness. High-depth sequencing enabled to identify driver genes and potential treatment targets in glioma.Methods: A whole exome sequencing analysis of 27 Chinese patients was conducted and somatic mutation signatures were analyzed using validated computational methods. The biological roles of SRPX mutations and subsequent regulatory mechanisms were revealed by common experimental methods.Results: We intriguingly found that SRPX drove glioma progression with two frequent in-frame deletion mutations of p.L14DEL and p.L23DEL. Mechanistically, both the two mutations of SRPX promoted binding with transcription factor AHR on its promoter, upregulated gene transcription of itself, then activated EGFR/ Akt/ Nestin pathway and contributed to aggressive tumor phenotypes and animal tumor growth. Further, knockdown of AHR or application of Akt inhibitor suppressed the oncogenic role of mutated SRPX.Conclusions: Our study highlighted the landscape of glioma in revealing a non-distinctive mutation and signaling pathway profile between low and high grades. More importantly, we identified a novel role of SRPX mutations in acceleration to stemness and malignant progression, which could provide new targets in improving outcomes of glioma.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High expression of the cachexia-related protein Fn14 in esophageal squamous cell carcinoma correlates with poor chemotherapy response and anti-Fn14 therapy decreases chemotherapeutic resistance. 恶病质相关蛋白Fn14在食管鳞状细胞癌中的高表达与化疗反应差相关，抗Fn14治疗可降低化疗耐药。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2025-07-15 DOI: 10.1038/s41416-025-03087-1

Kei Adachi, Kotaro Yamashita, Yu Kamakura, Kota Momose, Takuro Saito, Koji Tanaka, Tomoki Makino, Kazuyoshi Yamamoto, Tsuyoshi Takahashi, Yukinori Kurokawa, Kiyokazu Nakajima, Hidetoshi Eguchi, Yuichiro Doki

{"title":"High expression of the cachexia-related protein Fn14 in esophageal squamous cell carcinoma correlates with poor chemotherapy response and anti-Fn14 therapy decreases chemotherapeutic resistance.","authors":"Kei Adachi, Kotaro Yamashita, Yu Kamakura, Kota Momose, Takuro Saito, Koji Tanaka, Tomoki Makino, Kazuyoshi Yamamoto, Tsuyoshi Takahashi, Yukinori Kurokawa, Kiyokazu Nakajima, Hidetoshi Eguchi, Yuichiro Doki","doi":"10.1038/s41416-025-03087-1","DOIUrl":"https://doi.org/10.1038/s41416-025-03087-1","url":null,"abstract":"Background: In cancer cachexia, cytokine release by tumours causes weight loss, decreased therapeutic efficacy, and worsened prognosis. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and fibroblast inducible factor 14 (Fn14) are cancer cachexia-related proteins; however, their expression in oesophageal squamous cell carcinoma (ESCC) and association with therapeutic resistance remain unclear.Methods: We evaluated how Fn14 knockdown and overexpression in ESCC lines (TE6 and TE10) contributed to proliferation, migration, and chemotherapy resistance in vitro and in vivo. In 135 ESCC patients who underwent esophagectomy after neoadjuvant chemotherapy, tumour expression of TWEAK and Fn14 was evaluated immunohistochemically to assess the association with clinicopathological factors and prognosis, including chemotherapeutic efficacy.Results: Proliferation, migration, and chemotherapy resistance of ESCC cell lines were decreased by Fn14 knockdown but increased by Fn14 overexpression. Patients with Fn14-overexpressing ESCC had a decreased response rate to neoadjuvant chemotherapy and significantly lower rates of overall and recurrence-free survival, while concurrent expression of TWEAK and Fn14 was associated with further reductions in the response rate to chemotherapy and the rates of overall and recurrence-free survival.Conclusions: TWEAK and Fn14 expression was associated with treatment resistance and prognosis in ESCC. Inhibiting the TWEAK/Fn14 axis may reduce treatment resistance and improve prognosis.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fatigue in long-term cancer survivors: prevalence, associated factors, and mortality. A prospective population-based study. 长期癌症幸存者的疲劳：患病率、相关因素和死亡率。一项基于人群的前瞻性研究。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2025-07-15 DOI: 10.1038/s41416-025-03116-z

Melissa S Y Thong, Daniela Doege, Lena Koch-Gallenkamp, Heike Bertram, Andrea Eberle, Bernd Holleczek, Alice Nennecke, Annika Waldmann, Sylke Ruth Zeissig, Ron Pritzkuleit, Elmar Brähler, Hermann Brenner, Volker Arndt

{"title":"Fatigue in long-term cancer survivors: prevalence, associated factors, and mortality. A prospective population-based study.","authors":"Melissa S Y Thong, Daniela Doege, Lena Koch-Gallenkamp, Heike Bertram, Andrea Eberle, Bernd Holleczek, Alice Nennecke, Annika Waldmann, Sylke Ruth Zeissig, Ron Pritzkuleit, Elmar Brähler, Hermann Brenner, Volker Arndt","doi":"10.1038/s41416-025-03116-z","DOIUrl":"https://doi.org/10.1038/s41416-025-03116-z","url":null,"abstract":"Background: We compared fatigue severity in breast, prostate or colorectal cancer survivors 5-16 years post-diagnosis with cancer-free controls, and examined factors associated with fatigue and its association with all-cause mortality in survivors.Methods: Participants of the CAncEr Survivorship - A multi-Regional (CAESAR) study completed the Fatigue Assessment Questionnaire (FAQ) between 2009 and 2011. The FAQ assesses affective, cognitive, and physical fatigue, and sleep problems. We derived the odds of fatigue using logistic regression with the 75th percentile of population norms as the cut-off. All-cause mortality (up to end 2021) was estimated using Cox regression models.Results: The sample comprised 6057 survivors, of whom approximately one-third reported affective, cognitive, or physical fatigue. Demographic (age, relationship), clinical (chemotherapy), comorbidity (depression), lifestyle, and psychological factors were associated with higher odds of fatigue symptoms and total fatigue. Fatigue symptoms, predominantly physical fatigue, were strongly associated with mortality (unadjusted hazard ratios (HRs) ranged from 1.48 to 2.40). The HRs were attenuated after adjustment for comorbidities and depressive symptoms, although affective and physical fatigue remained independent risk factors for mortality.Conclusions: Demographic, clinical, comorbidity, lifestyle, and psychological factors were associated with fatigue in long-term survivors. Fatigued survivors have a higher mortality risk. Lowering the burden of fatigue by a comprehensive approach might result in better survival.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study. 更正：639例晚期高级消化神经内分泌肿瘤（NET G3和NEC）的前瞻性队列特征和治疗结果。北欧NEC 2研究。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2025-07-14 DOI: 10.1038/s41416-025-03095-1

Halfdan Sorbye, Geir Olav Hjortland, Lene Weber Vestermark, Morten Ladekarl, Johanna Svensson, Anna Sundlöv, Eva Tiensuu Janson, Herish Garresori, Eva Hofsli, Christian Kersten, Hege Elvebakken, Per Pfeiffer, Siren Morken, Jorg Assmus, Inger Marie Bowitz Lothe, Elizaveta Tabaksblat, Ulrich Knigge, Anne Couvelard, Aurel Perren, Seppo W Langer

引用次数: 0

Targeting ribosomes reprograms the tumour microenvironment and augments cancer immunotherapy. 靶向核糖体重编程肿瘤微环境和增强癌症免疫治疗。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2025-07-11 DOI: 10.1038/s41416-025-03109-y

Kaisa Cui, Bingxin Liu, Liang Gong, Quan Wan, Hong Tang, Zhicheng Gong, Renhui Shen, Chao Wang, Qiang Zhang, Qilin Li, Yizhun Zhu, Youming Zhang, Xiaojie Lu

{"title":"Targeting ribosomes reprograms the tumour microenvironment and augments cancer immunotherapy.","authors":"Kaisa Cui, Bingxin Liu, Liang Gong, Quan Wan, Hong Tang, Zhicheng Gong, Renhui Shen, Chao Wang, Qiang Zhang, Qilin Li, Yizhun Zhu, Youming Zhang, Xiaojie Lu","doi":"10.1038/s41416-025-03109-y","DOIUrl":"https://doi.org/10.1038/s41416-025-03109-y","url":null,"abstract":"Background: Hyperactive ribosome biogenesis is a hallmark of tumours. Current ribosome-related studies are concentrated on cancer cells. Ribosomes can regulate both tumour and non-cancer cells within the tumour microenvironment, yet the immunomodulatory effects of cellular ribosome biogenesis blockade remain inadequately understood.Methods: We performed ribosome-targeting therapy utilizing CX-5461, an effective and acknowledged selective inhibitor of ribosome biogenesis, in immunocompetent in vivo models and submitted for single-cell RNA sequencing (scRNA-seq). Additional large-scale human scRNA-seq data, in-house clinical samples and assays were used.Results: Ribosome inhibition elevated lymphoid cell cytotoxic granule secretion and macrophage pro-inflammation reprogramming. We uncovered unique immune cell subpopulations that are sensitive to ribosome biogenesis blockade and are associated with adverse clinical outcomes. Impressively, these cells regress during responsive immune checkpoint blockade (ICB) treatment, revealing that they are essential for immunotherapy efficacy. Moreover, targeting ribosomes induces immune checkpoint expression (such as Lag3) and significantly sensitizes tumours to anti-Lag3 immunotherapy, eliciting potent tumour regression and deeper anti-tumour immune responses.Conclusions: These findings unravel previously unrecognized roles of cellular ribosome biogenesis in sustaining immunosuppressive non-cancer cells. Our work unveils that ribosome biogenesis blockade could reinstate immunosurveillance and provide novel strategies to enhance the ICB efficacy in patients with poor immunogenicity.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer-associated fibroblasts are associated with neo-adjuvant treatment response in oesophageal adenocarcinoma. 癌相关成纤维细胞与食管癌新辅助治疗反应相关。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2025-07-10 DOI: 10.1038/s41416-025-03080-8

Robert C Walker, Stella P Breininger, Benjamin P Sharpe, Jack Harrington, Ian Reddin, Carmen Tse, Rushda Rajak, Annette Hayden, Saqib Rahman, Ben Grace, Fereshteh Izadi, Jonathan West, Maria Secrier, Zoë S Walters, Matthew J J Rose-Zerilli, Timothy J Underwood

{"title":"Cancer-associated fibroblasts are associated with neo-adjuvant treatment response in oesophageal adenocarcinoma.","authors":"Robert C Walker, Stella P Breininger, Benjamin P Sharpe, Jack Harrington, Ian Reddin, Carmen Tse, Rushda Rajak, Annette Hayden, Saqib Rahman, Ben Grace, Fereshteh Izadi, Jonathan West, Maria Secrier, Zoë S Walters, Matthew J J Rose-Zerilli, Timothy J Underwood","doi":"10.1038/s41416-025-03080-8","DOIUrl":"https://doi.org/10.1038/s41416-025-03080-8","url":null,"abstract":"Background: Neoadjuvant treatment (NAT) in oesophageal adenocarcinoma (EAC) is characterised by differential responses between patients and treatment modalities. The components of the tumour microenvironment (TME) that contribute to this are unknown. We explored this, focusing on cancer-associated fibroblasts (CAF) an abundant TME component.Methods: We performed histopathologic, single-cell RNA sequencing and transcriptomic analysis on 26 patients, stratified by pathological response to NAT, and validated a prognostic model in genomic consortia cohorts. Patient-derived cells were used to model CAF phenotypes in vitro.Results: We observed changes in the TME in response to the NAT received. Specific changes in fibroblasts correlated with treatment response and altered gene expression associated with NAT type. Three myofibroblastic phenotypes dominate the TME, two of which persist in non-responders and could only be partially re-capitulated in vitro using co-culture with cancer cells or TGF-β. A two-gene NAT fibrotic signature was an independent prognostic indicator in chemo/chemoradiotherapy treated patients (HR = 2.47, p = 0.029).Conclusions: This study provides a compendium of cell phenotypes in EAC across the current NAT treatment pathway that provides insights into CAF biology and cancer progression. MyoCAFs represent an axis to repurpose agents to enhance current therapies and immunotherapy.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A study of subjective memory impairment in long-term testicular cancer survivors. 长期睾丸癌幸存者主观记忆障碍的研究。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2025-07-10 DOI: 10.1038/s41416-025-03108-z

Alv A Dahl, Sophie D Fosså

{"title":"A study of subjective memory impairment in long-term testicular cancer survivors.","authors":"Alv A Dahl, Sophie D Fosså","doi":"10.1038/s41416-025-03108-z","DOIUrl":"https://doi.org/10.1038/s41416-025-03108-z","url":null,"abstract":"Background: Memory impairment is a common late adverse effect in survivors of many cancer types, but there are few studies of long-term survivors of testicular cancer (LTCSs). The aims of this study were to examine memory impairment in LTCSs both longitudinally and cross-sectionally, and to compare the cross-sectional findings with normative data.Methods: A national sample of 753 LTCSs filled in questionnaires at means of 12 and 28 years after diagnosis. Memory impairment was reported by the Meta-Memory Questionnaire at 28 years. Longitudinal and cross-sectional associations between independent variables and memory impairment were examined with linear regression analyses.Results: At 28 years mean memory impairment scores in LTCSs hardly differed from normative values in 10-year age groups from 40 to 79 years. Many variables were significantly associated with memory impairment in univariate regression analyses both cross-sectionally and longitudinally. In multivariable analyses total fatigue was significantly associated with memory impairment longitudinally, and with total fatigue and increased neuropathy cross-sectionally.Conclusions: LTCSs at 28 years since diagnosis do not have increased level of memory impairment compared to normative data. In case of memory impairment complaints in LTCSs, several risk factors should be examined and some of them are amenable to interventions.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HPValidate-human papillomavirus testing with DNA and mRNA assays on self-collected samples in cervical screening: comparison of test characteristics on three self-sampling devices. 宫颈筛查中自采样本的hpv验证-人乳头瘤病毒DNA和mRNA检测：三种自采装置检测特征的比较

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2025-07-08 DOI: 10.1038/s41416-025-03102-5

Christopher S Mathews, Alexandra Sargent, Kate Cuschieri, Matejka Rebolj, Adam R Brentnall, Anne Mackie, Charlotte Mills, Carolina Martinelli, Ann-Marie Wright, Katherine Hunt, Andrew Bird, Hasit Patel, David Smith, Trudy Johnson, Kay Ellis, Mark Hunt, Karin Denton

{"title":"HPValidate-human papillomavirus testing with DNA and mRNA assays on self-collected samples in cervical screening: comparison of test characteristics on three self-sampling devices.","authors":"Christopher S Mathews, Alexandra Sargent, Kate Cuschieri, Matejka Rebolj, Adam R Brentnall, Anne Mackie, Charlotte Mills, Carolina Martinelli, Ann-Marie Wright, Katherine Hunt, Andrew Bird, Hasit Patel, David Smith, Trudy Johnson, Kay Ellis, Mark Hunt, Karin Denton","doi":"10.1038/s41416-025-03102-5","DOIUrl":"https://doi.org/10.1038/s41416-025-03102-5","url":null,"abstract":"Background: Relative test accuracy of human papillomavirus (HPV) testing on self vs. clinician-collected samples may depend on the specific combination of a self-sampling device and HPV assay.Methods: Five self-sampling workflows were studied within the routine English cervical screening programme; the cobas HPV DNA and APTIMA HPV mRNA assays with the Evalyn brush, Self Vaginal FLOQSwabs (FLOQSwabs) and the Multitest kit. To study test sensitivity, women were recruited at routine colposcopy appointments; to study test specificity, women were recruited at routine screening appointments.Results: The estimated conditional relative sensitivity for high-grade cervical intraepithelial neoplasia (CIN2+) was 0.90 (90% CI: 0.84-0.94) for the Evalyn + cobas workflow, 0.94 (0.90-0.97) for FLOQSwabs + cobas, 0.77 (0.69-0.83) for Evalyn + APTIMA, 0.92 (0.85-0.96) for FLOQSwabs+APTIMA and 0.92 (0.86-0.96) for Multitest+APTIMA. The estimates of the relative specificity were 0.96 (0.95-0.98), 0.91 (0.90-0.93), 0.99 (0.97-1.01), 0.89 (0.87-0.92) and 0.87 (0.85-0.89), respectively. The specificity estimates were sensitive to the inclusion of certain subgroups of women. HPV detection rates were higher for all self-sample than clinician-sample workflows.Conclusions: The relative test sensitivity of four self-sampling workflows including both DNA and mRNA HPV assays was relatively close to that associated with clinician-collected samples.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of change in physical activity with use of outpatient specialist care and hospitalisations among breast cancer survivors with type 2 diabetes in Sweden. 瑞典2型糖尿病乳腺癌幸存者身体活动变化与门诊专科护理和住院治疗的关系

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2025-07-04 DOI: 10.1038/s41416-025-03099-x

Genevieve Allen, Emerald G Heiland, Stanley Teleka, Ingrid Glimelius, Karl Michaëlsson, Liisa Byberg, Hannah L Brooke

{"title":"Association of change in physical activity with use of outpatient specialist care and hospitalisations among breast cancer survivors with type 2 diabetes in Sweden.","authors":"Genevieve Allen, Emerald G Heiland, Stanley Teleka, Ingrid Glimelius, Karl Michaëlsson, Liisa Byberg, Hannah L Brooke","doi":"10.1038/s41416-025-03099-x","DOIUrl":"https://doi.org/10.1038/s41416-025-03099-x","url":null,"abstract":"Background: Studies in breast cancer patients have consistently shown that physical activity improves survival. We examined if change in physical activity from before to after a breast cancer diagnosis is associated with outpatient specialist care use and hospitalisations in women with type 2 diabetes mellitus (T2DM).Methods: This register-based cohort study included 2145 women with T2DM who self-reported frequency of walking 30 min/week, 1-3 years before and after their breast cancer diagnosis (diagnosed 2004-2018). Women were grouped as: maintained inactive (reference), increased activity, decreased activity, or maintained active. Using multivariable-adjusted Cox proportional hazards models, we assessed change in physical activity with time to 1) first hospital admission and 2) first outpatient specialist care/hospitalisation for 15 International Classification of Disease chapters in the National Patient Register.Results: Women who maintained active (hazard ratio[95% CI]: 0.68[0.58-0.80]) or increased (0.72[0.58-0.88]) activity, but not those who decreased (0.92[0.79-1.08]) activity, had a lower rate of hospitalisations during follow-up than inactive women. Results were similar for infection, malignancy, blood disorders, general symptoms, mental/behavioural health.Conclusion: In breast cancer survivors, treated with curative intention, with T2DM, maintaining or increasing walking to ≥3times/week was associated with lower rates of hospitalisations overall and specialist outpatient care/hospitalisations across a range of diagnoses.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144564592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges and perspectives of CAR-T cell therapy in solid tumours: insights from gastric cancer. CAR-T细胞治疗实体肿瘤的挑战和前景：来自胃癌的见解。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2025-07-04 DOI: 10.1038/s41416-025-03100-7

Jincai Zhou

{"title":"Challenges and perspectives of CAR-T cell therapy in solid tumours: insights from gastric cancer.","authors":"Jincai Zhou","doi":"10.1038/s41416-025-03100-7","DOIUrl":"https://doi.org/10.1038/s41416-025-03100-7","url":null,"abstract":"Gastric cancer (GC) remains a significant challenge as it is one of the most prevalent and lethal malignancies worldwide. Due to its complexity characterised by diverse histological subtypes and genetic mutations, its management and treatment remain a substantial challenge. Recent advancements in surgery, chemotherapy, and radiation therapy have only marginally improved the prognosis for advanced GC, underscoring the urgent need for innovative therapeutic strategies. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a breakthrough in haematologic malignancies and is now being investigated as a potential treatment for solid tumours. The remarkable efficacy of CAR-T in GC has been demonstrated in both preclinical and clinical studies. Potential biomarkers for GC treatment include CLDN18.2, MSLN, CEA, EpCAM, MUC1, HER2, FOLR1, and NKG2DL. However, applying CAR-T cells directed against GC still faces considerable challenges. Novel CAR designs have the potential to enhance CAR-T cell therapy for GC by facilitating T cell infiltration, enhancing T cell persistence, reducing on-target off-tumour toxicity, improving tolerance to the immunosuppressive tumour microenvironment (TME), and bolstering interactions with heterogeneous antigens. This review summarises relevant preclinical studies and clinical progress in CAR-T cell therapy for GC, evaluates its therapeutic potential and safety, discusses current challenges, and outlines future directions for clinical translation.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144564598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0